Patents by Inventor Akinori Arimura
Akinori Arimura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140243351Abstract: A medicament for treating allergic rhinitis, characterized in that (A) a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, is combined with (B) at least one compound selected from the group consisting of cetirizine, fexofenadine, and loratadine, or a pharmaceutically acceptable salt thereof. Since the effects of the medicament for treating allergic rhinitis of the present invention surpass the sum of the effects of single dose of each of the agents against the allergic rhinitis, the medicament is useful as a medicament for treating allergic rhinitis having potent effects.Type: ApplicationFiled: September 28, 2012Publication date: August 28, 2014Inventors: Takuko Sawada, Akinori Arimura, Goro Kuwajima
-
Patent number: 7220783Abstract: The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or weakly suppresses the production of IgG, IgM and/or IgA which are produced at the same time, a compound of the formula (I): wherein R1–R13 are hydrogen, halogen, lower alkyl, lower alkoxy or the like, X is —O—, —CH2—, —NR14— or —S(O)p- and Y is lower alkyl, lower alkenyl or the like, a process for producing the same and a pharmaceutical composition comprising the same.Type: GrantFiled: November 12, 2003Date of Patent: May 22, 2007Assignee: Shionogi & Co., Ltd.Inventors: Kenji Kawada, Mitsuaki Ohtani, Ryuji Suzuki, Akinori Arimura
-
Publication number: 20070027144Abstract: An inhibitor for an inflammatory cell infiltration in the respiratory tract, an inhibitor for hyperirritability in the respiratory tract, a muciparous inhibitor, or a bronchodilator which contains as an active ingredient a compound represented by the formula (I) or (II): wherein R1 is the group represented by the formula: —C(=Z)-W—R4 wherein Z is an oxygen atom or the like; W is an oxygen atom or the like; R4 is optionally substituted alkyl or the like; R2 and R3 are independently optionally substituted alkyl or the like; or R2 and R3 are taken together to form optionally substituted alkylene which may contain a heteroatom(s); m is an integer of 0 to 2; A is optionally substituted aryl or optionally substituted heteroaryl; wherein R5 is the group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 and Y3 are each independently a bond or the like; Y2 is —C(?O)—NRb— or the like; Ra is optionally substituted alkyl, or the like; Rb is a hydrogen atom or the like; R6 is a hydrogen atom or the like;Type: ApplicationFiled: August 16, 2004Publication date: February 1, 2007Applicant: SHIONOGI & CO., LTD.Inventor: Akinori Arimura
-
Patent number: 7105564Abstract: The present invention provides novel compounds having a dual antagonistic activity against thromboxane A2 receptor and prostaglandin D2 receptor and pharmaceutical compositions comprising them. A compound of the formula (I): wherein R1 is —CH2—CH?CH—CH2—CH2—CH2—COOR2 or —CH?CH—CH2—CH2—CH2—COOR2; R2 is hydrogen or alkyl; m is 0 or 1; p is 0 or 1; X1 and X3 each is independently optionally substituted aryl or optionally substituted heteroaryl; X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, or the like; X4 is —CH2—, —CH2—CH2—, —C(?O)—, or the like, have a dual antagonistic activity against both a thromboxane A2 receptor and a prostaglandin D2 receptor.Type: GrantFiled: March 2, 2000Date of Patent: September 12, 2006Assignee: Shionogi & Co., Ltd.Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu, Akinori Arimura
-
Patent number: 7101915Abstract: The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or weakly suppresses the production of IgG, IgM and/or IgA which are produced at the same time, a compound of the formula (I): wherein R1–R13 are hydrogen, halogen, lower alkyl, lower alkoxy or the like, X is —O—, CH2—, —NR14— or —S(O)p— and Y is lower alkyl, lower alkenyl or the like, a process for producing the same and a pharmaceutical composition comprising the same.Type: GrantFiled: July 30, 1997Date of Patent: September 5, 2006Assignee: Shionogi & Co., Ltd.Inventors: Kenji Kawada, Mitsuaki Ohtani, Ryuji Suzuki, Akinori Arimura
-
Patent number: 7084136Abstract: A compound of the formula (I): wherein A is alkylene optionally having an unsaturated bond; R is —C(?O)—R1; R1 is hydroxy or the like; m is 0 or 1; p is 0 or 1; X1 and X3 are each independently optionally substituted aryl or optionally substituted heteroaryl or the like; X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, or the like; X4 is —CH2—, —CH2—CH2—, —C(?O)—, or the like, having a dual antagonistic activity against both a thromboxane A2 receptor and a prostaglandin D2 receptor is found.Type: GrantFiled: May 28, 2001Date of Patent: August 1, 2006Assignee: Shionogi & Co., Ltd.Inventors: Norihiko Tanimoto, Akinori Arimura
-
Patent number: 7074836Abstract: The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or weakly suppresses the production of IgG, IgM and/or IgA which are produced at the same time, a compound of the formula (I): wherein R1–R13 are hydrogen, halogen, lower alkyl, lower alkoxy or the like, X is —O—, —CH2—, NR14— or —S(O)p— and Y is lower alkyl, lower alkenyl or the like, a process for producing the same and a pharmaceutical composition comprising the same.Type: GrantFiled: November 12, 2003Date of Patent: July 11, 2006Assignee: Shionogi & Co., Ltd.Inventors: Kenji Kawada, Mitsuaki Ohtani, Ryuji Suzuki, Akinori Arimura
-
Patent number: 7008954Abstract: The present invention provides a pharmaceutical composition for use as a Th2 differentiation inhibitor comprising a compound represented by Formula (I): wherein each of ring A, ring B and ring C is an aromatic carbocyclic ring, a heterocyclic ring and the like, X is a single bond, —O—, —CH2—, —NH—, —SO— and the like, Y is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl and the like, each of V1 and V2 is a single bond, —O—, —NH—, —OCH2— and the like, a prodrug, pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: July 14, 2000Date of Patent: March 7, 2006Assignee: Shionogi & Co., Ltd.Inventors: Akinori Arimura, Kenji Kawada
-
Publication number: 20040127495Abstract: The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or weakly suppresses the production of IgG, IgM and/or IgA which are produced at the same time, a compound of the formula (I): 1Type: ApplicationFiled: November 12, 2003Publication date: July 1, 2004Applicant: Shionogi & Co., Ltd.Inventors: Kenji Kawada, Mitsuaki Ohtani, Ryuji Suzuki, Akinori Arimura
-
Publication number: 20040024019Abstract: A compound of the formula (I): 1Type: ApplicationFiled: December 2, 2002Publication date: February 5, 2004Inventors: Norihiko Tanimoto, Akinori Arimura
-
Publication number: 20030027854Abstract: A PGD2 receptor antagonist such as a compound of the formula (IA-a-5): 1Type: ApplicationFiled: April 23, 2002Publication date: February 6, 2003Applicant: Shionogi & Co., Ltd.Inventor: Akinori Arimura
-
Patent number: 6506789Abstract: A PGD2 receptor antagonist such as a compound of the formula (IA-a-5): a pharmaceutical acceptable salt thereof or a hydrate thereof, has an efficacious activity for the prevention or treatment of itching and is useful as a medicament.Type: GrantFiled: June 18, 2001Date of Patent: January 14, 2003Assignee: Shionogi & Co., Ltd.Inventor: Akinori Arimura
-
Patent number: 6498190Abstract: A compound of the formula (I): wherein for example, a compound below: wherein R1 is CH3, H or Na; and X1—X2—X3 is or its salt or a hydrate thereof is useful as PGD2 antagonist and can be used as a drug for treating diseases in which mast cell dysfunction is involved, for example, systemic mastocytosis and disorder of systemic mast cell activation, and also tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, injury due to ischemic reperfusion, and as an anti-inflammatory agent. It is particularly useful in the treatment of nasal occlusion.Type: GrantFiled: February 18, 2000Date of Patent: December 24, 2002Assignee: Shionogi & Co., Ltd.Inventors: Mitsuaki Ohtani, Akinori Arimura, Tatsuo Tsuri, Junji Kishino, Tsunetoshi Honma
-
Publication number: 20020058693Abstract: A PGD2 receptor antagonist such as a compound of the formula (IA-a-5): 1Type: ApplicationFiled: June 18, 2001Publication date: May 16, 2002Inventor: Akinori Arimura
-
Patent number: 6384075Abstract: A compound of the formula (I): wherein: for example, a compound below: wherein: R1 is CH3, H or Na; and X1—X2—X3 is: or its salt or a hydrate thereof is useful as PGD2 antagonist and can be used as a drug for treating diseases in which mast cell dysfunction is involved, for example, systemic mastocytosis and disorder of systemic mast cell activation, and also tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, injury due to ischemic reperfusion, and as an anti-inflammatory agent. It is particularly useful in the treatment of nasal occlusion.Type: GrantFiled: February 18, 2000Date of Patent: May 7, 2002Assignee: Shionogi & Co., Ltd.Inventors: Mitsuaki Ohtani, Akinori Arimura, Tatsuo Tsuri, Junji Kishino, Tsunetoshi Honma
-
Patent number: 6172113Abstract: A compound of the formula (I): wherein for example, a compound below: wherein R1 is CH3, H or Na; and X1-X2-X3 is or its salt or a hydrate thereof is useful as PGD2 antagonist and can be used as a drug for treating diseases in which mast cell dysfunction is involved, for example, systemic mastocytosis and disorder of systemic mast cell activation, and also tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, injury due to ischemic reperfusion, and as an anti-inflammatory agent. It is particularly useful in the treatment of nasal occlusion.Type: GrantFiled: April 22, 1998Date of Patent: January 9, 2001Assignee: Shionogi & Co., Ltd.Inventors: Mitsuaki Ohtani, Akinori Arimura, Tatsuo Tsuri, Junji Kishino, Tsunetoshi Honma
-
Patent number: 6083974Abstract: A compound, a pharmaceutically acceptable salt thereof, or a hydrate thereof having PGD.sub.Type: GrantFiled: May 17, 1999Date of Patent: July 4, 2000Assignee: Shionogi & Co., Ltd.Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu, Akinori Arimura
-
Patent number: 6069166Abstract: A compound, pharmaceutically acceptable salt thereof, or hydrate thereof having a PGD.sub.2 -antagonistic activity, and an inhibitory activity against infiltration of eosinophils, useful for treating mast cell dysfunction-associated diseases, such as systemic mastocytosis and disorder of systemic mast cell activation, as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, inflammation and atopic dermatitis, which is shown by the formula (I): ##STR1## is provided.Type: GrantFiled: May 28, 1999Date of Patent: May 30, 2000Assignee: Shionogi & Co., Ltd.Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu, Akinori Arimura